Compare Summit Therapeutics Inc (SMMT) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vale SA — how do they compare? Summit Therapeutics Inc trades at $17.25 (market cap $13.71B), while Vale SA trades at $13.51 (market cap $57.32B). The key difference: Vale SA is far larger — about 4.2× Summit Therapeutics Inc's market cap, and Vale SA pays a 8.87% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vale SA for 109 Days on average.
| SMMT | VALE | |
|---|---|---|
Market Cap | $13.71B | $57.32B |
Volume | 6,173,057 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $26.38 | $17.82 |
52-Week Low | $12.43 | $10.75 |
Typical Hold Time | 16 Days | 109 Days |
Enterprise Value | $13.04B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
VALE trades at $13.50, down 0.81% with bearish technical signals. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 EPS expected at $0.42. Revenue declined from $43.8B in 2022 to $38.4B in 2025, though 2026 projections show a slight recovery to $41.2B. Analyst consensus is mixed with 32% buy ratings but a $16.21 price target suggesting 20% upside. Recent news highlights cost pressures and regulatory risks in Brazil.
VALE faces headwinds from declining iron ore margins and rising operational costs, but maintains strong cash flow and dividend payments. The base metals segment shows growth potential, though cyclical exposure and Brazilian regulatory uncertainty pose significant risks. With current valuation metrics appearing reasonable (P/E 26.8, P/B 1.5), the stock offers value for patient investors willing to navigate commodity volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
